Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study
Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0–17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.
KeywordsCannabidiol Medical cannabis Medical marijuana Autism spectrum disorder Disruptive behavior
AA: Study conception and design; acquisition, analysis and interpretation of data; drafted manuscript; critically revised manuscript and gave final approval. CH and LA: Study conception; interpretation of data; critically revised manuscript and gave final approval. WN: Study design; acquisition of data; critically revised manuscript and gave final approval. EH: Study design; acquisition, analysis and interpretation of data; drafted manuscript; critically revised manuscript and gave final approval.
The authors received no financial support for the research, authorship, and/or publication of this article.
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., et al. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106. https://doi.org/10.1177/1362361314524641.CrossRefPubMedGoogle Scholar
- Ballaban-Gil, K., & Tuchman, R. (2000). Epilepsy and epileptiform EEG: Association with autism and language disorders. Mental Retardation and Developmental Disabilities Research Reviews, 6(4), 300–308, https://doi.org/10.1002/1098-2779(2000)6:4%3C300::aid-mrdd9%3E3.0.co;2-r.CrossRefPubMedGoogle Scholar
- Campos, A. C., Fogaca, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., et al. (2017). Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Frontiers in Pharmacology, 8, 269. https://doi.org/10.3389/fphar.2017.00269.CrossRefPubMedPubMedCentralGoogle Scholar
- Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America, 114(42), 11229–11234. https://doi.org/10.1073/pnas.1711351114.CrossRefPubMedPubMedCentralGoogle Scholar
- Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., et al. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9, 18. https://doi.org/10.1186/s13229-018-0203-y.CrossRefPubMedPubMedCentralGoogle Scholar
- King, B. H., Dukes, K., Donnelly, C. L., Sikich, L., McCracken, J. T., Scahill, L., et al. (2013). Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial. JAMA Pediatrics, 167(11), 1045–1052. https://doi.org/10.1001/jamapediatrics.2013.2698.CrossRefPubMedPubMedCentralGoogle Scholar
- Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 391(10125), 1085–1096. https://doi.org/10.1016/s0140-6736(18)30136-3.CrossRefPubMedGoogle Scholar